Chen A, Stecker E, Warden BA Direct oral anticoagulant use: a practical guide to common clinical challenges. JAHA. 2020; 9:(13)

DOACs to be analysed as part of genetic biobank scheme. 2024. http// (accessed 22 February 2024)

Gheorghe-Andrei D, Martinez-Rubio A, Agewall S Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). Europace. 2018; 20:(5)731-732

National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management [NG196]. 1.6 Stroke prevention. 2021a. https// (accessed 22 February 2024)

National Institute for Health and Care Excellence. Shared decision making [NG197]. 2021b. https// (accessed 22 February 2024)

Mendes A Patient treatment matching through genomic medicine. J Presc Pract. 2019; 1:(1)

Genomic medicine is going mainstream and pharmacists need to be prepared. 2017. http// (accessed 22 February 2024)

Steffel J, Verhamme P, Potpara TS The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39:(16)1330-1393

Use of genomic medicine to uncover adverse effects related to direct oral anticoagulants

02 March 2024
Volume 6 · Issue 3

Having blasted onto the scene back in 2010 to provide a novel alternative to the previous standard of care in anticoagulation, direct oral anticoagulants (DOACs) have since become an attractive treatment option for prescribers and patients (Chen et al, 2020). However, as with all treatments, DOACs are not without their side effects.

In a new development, the Medicines and Healthcare products Regulatory Agency (MHRA) recently announced its intention to work with Genomics England to analyse patients' experiences of side effects reported from the use of DOACs. This will take place as part of a genetic biobank version of the Yellow Card adverse events reporting scheme, and will make use of gene sequencing to analyse the ways in which a person's genetic make-up may influence their response to DOACs (Clews, 2024).

The genetic biobank, which operates alongside the Yellow Card scheme and is thought to be first in the world, facilitates patient-reported suspected adverse effects of medicines and medical devices. It then stores genetic data and samples with the aim of identifying whether genetic traits are linked to the adverse reactions patients have experienced.

Register now to continue reading

Thank you for visiting Journal of Prescribing Practice and reading some of our peer-reviewed resources for prescribing professionals. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month